Dublin, Dec. 17, 2021 (GLOBE NEWSWIRE) — The report “Global Microneedle Drug Delivery Systems Market By Type, By Material, By Application, By Regional Outlook, Industry Analysis Report and Forecast, 2021 – 2027” has been added to ResearchAndMarkets.com’s to offer.
The global Microneedle Drug Delivery Systems market is projected to reach $9.1 Billion by 2027, rising at a market growth rate of 7.8% CAGR during the forecast period. The microneedled drug delivery device is designed with the arrangement of hundreds of microneedles in a small patching order to pass a large supply of the drug to provide a needed therapeutic response.
This device aids in the direct delivery of the drug into the viable epidermis without coming into contact with blood vessels and nerve fibers present in the dermal layers. Silicon, carbohydrates, silica glass, polymers and ceramics are some of the materials used in the manufacture of microneedles. In general, microneedles are hundreds of microns long and up to 1 to 50mm wider at the tip and nearly 50-300mm at the base.
The factors accelerating the growth of the microneedle medicine market are increasing the demand for a safer alternative to conventional hypodermic injections and increasing research and development initiatives. In addition, the microneedle drug delivery systems have been over-adopted due to emerging safety issues affecting short- and long-term implications for patients, regulators, healthcare administrators, and clinicians. As indicated by the Centers for Disease Control and Prevention, an innovative patch could facilitate the administration of the vaccine to people suffering from measles and other vaccine-preventable diseases.
COVID-19 Impact Analysis
The healthcare sector was hit hard and faced numerous challenges. With the exception of the COVID patient, all other treatments were suspended to minimize the possibility of viral transmission. Demand for medical devices and equipment declined, leading to declining demand for microneedle drug delivery systems in the market. However, as the treatments of a number of patients are being suspended, the demand and growth of several markets are expected to increase again in the post-COVID period, including the market for microneedle drug delivery systems.
Market growth factors:The growth in the occurrence of preterm birth
The increase in preterm births in emerging countries and the increase in childhood malnutrition are expected to drive the demand for microneedle drug delivery systems market during the forecast period. A significant number of preterm births are noted in emerging countries such as India, Indonesia, Nigeria and the Philippines.
In addition, the increase in the adoption of microneedle drug delivery systems for preterm infants results in better neurological growth, improved intrauterine nutrient deposition and lower risk of complications, increasing their survival rate.
Higher prevalence of several chronic diseases
Different types of diseases such as head and neck cancer, esophageal cancer, Crohn’s disease, ulcerative colitis, gastric cancer and laryngeal cancer can have an impact on the oral food consumption of the patients. As they become more common, the microneedle drug delivery system market is expected to be propelled in the coming years.
In addition, the increasing number of people suffering from various childhood diseases such as asthma, tuberculosis, leukemia, chickenpox, bronchitis and anemia, coupled with the increase in the geriatric population that is more vulnerable to chronic diseases, is expected to boost the demand for microneedles. drug delivery systems for years to come.
Market limiting factor:Length and size of microneedles leads to severe pain
Microneedles are available in different sizes, lengths and types. The longer microneedles can cause excessive pain during the procedure. Because the microneedles are longer, they hit the deepest layer of the skin, causing severe pain to the patient. Thus, overuse of microneedles for vaccine or drug delivery can lead to severe patient pain, which is expected to reduce the demand for the microneedle drug delivery systems in the coming years.
Based on type, the market is segmented into hollow, dissolving, solid, coated and other types. The dissolving microneedle segment is expected to grow at the fastest CAGR in the coming years. The delivery of active ingredients by dissolving microneedles is a less painful procedure compared to the syringe. Once the needle is inserted into the skin, it will not be taken out as it will automatically dissolve into the skin.
Based on material, the microneedle drug delivery system market is divided into silicon, metal, polymer, and others. In 2020, the metal materials segment gained the largest market share in the microneedle drug delivery system market. The most commonly used metals are titanium and stainless steel. Other types of metals also used are palladium-cobalt alloys, palladium and nickel. These metals include biocompatibility and mechanical properties.
On the basis of application, the market has been segmented into drug delivery, cancer therapy, vaccine delivery, pain management, dermatology, and other applications. In 2020, the drug delivery segment achieved the maximum share of sales. The insulin hormone is made up of peptides. Patients with high blood sugar are recommended to use insulin. Several experiments were conducted by different scientists and these experiments confirmed that administering insulin through a microneedle is the best way, helping to produce the proper biological effects and maintain blood glucose levels.
Based on regions, the market is segmented into North America, Europe, Asia-Pacific, and Latin America, Middle East, and Africa. Asia-Pacific is expected to show the fastest growth in the forecast years. The emergence of COVID-19 has exposed the vulnerabilities in the regional healthcare sector. In addition, there is also a lack of interconnections between economic stability and health security.
The market research report deals with key stakeholder analysis of the market. Key companies profiled in the report include AdminMed nanoBioSciences LLC, Becton, Dickinson and Company, Zosano Pharma Corporation, Raphas co. ltd., Nanopass Technologies Ltd., Corium International, Inc., Gurnet Point Capital), Valeritas, Inc. (Zealand Pharma), Nitto Denko Corporation, Endoderma Ltd. and Innovation Medical Technology Limited.
Chapter 3. Recent Sector-Wide Strategic Developments – Global 3.1 Partnerships, collaborations and agreements 3.2 Product introductions and product extensions 3.3 Acquisitions and mergers 3.4 Geographical Expansions 3.5 Best Winning Strategies 3.5.1 Key Leading Strategies: Percentage Breakdown (2017-2021) 3.5.2 Key Strategic Step: (Product Launches and Product Expansions: 2017, June – 2021, June) Leading Players
Chapter 4. Global Microneedle Drug Delivery Systems Market by Application: 4.1 Global Hollow Market by Regions 4.2 Global Solvent Market by Regions: 4.3 Global Solid Market by Regions 4.4 Global Coated Market by Regions: 4.5 Global Other Species Market by Regions:
Chapter 5. Global Microneedle Drug Delivery Systems Market Segment By Application: 5.1 Global Drug Delivery Market by Regions: 5.2 Global Cancer Therapy Market by Regions: 5.3 Global Vaccine Market by Regions: 5.4 Global Pain Relief Market by Regions: 5.5 Global Dermatology Market by Regions: 5.6 Global Other Applications Market by Regions:
Chapter 6. Global Microneedle Drug Delivery Systems Market Analysis by Material 6.1 Global Metals Market by Regions 6.2 Global Polymer Market by Regions 6.3 Global Silicon Market by Regions 6.4 Global Other Material Market by Regions:
Chapter 7. Global Microneedle Drug Delivery Systems Market by Regions:
Chapter 8. Company Profiles 8.1 Nitto Denko Corporation 8.1.1 Company overview 8.1.1 Financial analysis 8.1.2 Segmental and regional analysis 8.1.3 Research and development costs 8.1.4 Recent strategies and developments: 220.127.116.11 Partnerships, collaborations and agreements: 18.104.22.168 Product introductions and product extensions: 8.2 Becton, Dickinson and Company 8.2.1 Company overview 8.2.2 Financial analysis 8.2.3 Segmental and regional analysis 8.2.4 Research and development costs 8.2.5 Recent strategies and developments: 22.214.171.124 Partnerships, collaborations and agreements: 126.96.36.199 Acquisitions and Mergers: 188.8.131.52 Geographical Extensions: 8.3 AdminMed nanoBioSciences LLC 8.3.1 Company overview 8.4 Zosano Pharma Corporation 8.4.1 Company overview 8.4.2 Recent strategies and developments: 184.108.40.206 Partnerships, collaborations and agreements: 8.5 Raphas Co., Ltd. 8.5.1 Company overview 8.6 Nanopass Technologies Ltd. 8.6.1 Company overview 8.6.2 Recent strategies and developments: 220.127.116.11 Partnerships, collaborations and agreements: 8.7 Corium Inc. (Gurnet Point Capital) 8.7.1 Company overview 8.7.2 Recent strategies and developments: 18.104.22.168 Partnerships, collaborations and agreements: 8.8 Zeeland Pharma A/S (Valeritas, Inc.) 8.8.1 Company overview 8.8.2 Financial analysis 8.8.3 Research and development costs 8.8.4 Recent strategies and developments: 22.214.171.124 Geographical Extensions: 8.9 Endoderma Co., Ltd. 8.9.1 Company overview 8.9.2 Recent strategies and developments: 126.96.36.199 Geographical Extensions: 8.10. Innoture Medical Technology Limited 8.10.1 Company overview
For more information on this report, please visit https://www.researchandmarkets.com/r/4317tt
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900